MDX 1303
Alternative Names: Anthrax anti-toxin monoclonal antibody - Altimmune/Medarex/Bristol-Myers-Squibb; Anti-anthrax monoclonal antibody - Altimmune/Medarex/Bristol-Myers-Squibb; MAb-1303; MDX-1303; ValortimLatest Information Update: 04 Nov 2017
At a glance
- Originator Medarex
- Developer Altimmune; Bristol-Myers Squibb; Medarex
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Anthrax toxin inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anthrax
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Anthrax(Prevention, In volunteers) in USA (IM, Injection)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Anthrax(Prevention, In volunteers) in USA (IV, Infusion)
- 04 May 2017 PharmAthene merged with Altimmune and the combined entity was renamed as Altimmune